The Dopamine Receptors
As sites of action for drugs used to treat schizophrenia and Parkinson’s disease, dopamine receptors are among the most validated drug targets for neuropsychiatric disorders. Dopamine receptors are also drug targets or potential targets for other disorders such as substance abuse, depression, Tourette’s syndrome, and attention deficit hyperactivity disorder. Updated from the successful first edition, "The Dopamine Receptors" serves as a reference work on dopamine receptors while also highlighting the areas of research that are most active today. To achieve this goal, authors have written chapters that set a broad area of research in its historical context, rather than focusing on the research output of their own laboratories.
Relies heavily on new knowledgeThe use of knock-out mice and subtype-selective drugs merit discussion in stand-alone chapters The field of G protein-coupled receptors has advanced significantly since the publication of the first edition, with a model of GPCR signaling based on linear, compartmentalized pathways having been replaced by a more complex, richer model in which neurotransmitter effects are mediated by a signalplex composed of numerous signaling proteins, including multiple GPCRs, other types of receptors, such as ionotropic receptors, accessory and scaffolding proteins, and effectorsKey aspects of this advanced model are specifically addressed in new chapters on dopamine receptor-interacting proteins and on dopamine receptor oligomerization